Alkem Laboratories Ltd. News and Updates

Name: Latest research reports of Alkem Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Alkem Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Alkem Laboratories Ltd. from all sources in a single place.

Load latest

Alkem Laboratories Ltd.

02 Nov 2018

5433.00

-1.36%

Strong show; outlook remains promising

Buy: Alkem Laboratories Ltd.

Motilal Oswal

2 November 2018 muted growth of 3%YoY to INR19.2b (v/s est. of INR17.5b) on back of 6% YoY decline in domestic formulation (DF, 69% of sales), which was off-set by strong 55% YoY growth in the US business (25% of sales). Gross margins declined by ~180bp YoY (flat QoQ) to ~60.2% due to increased share of relatively low margin US business. Increased other expenses and employee cost (up ~270bp and ~60bp, as percentage of sales) led to contraction of ~570bp YoY in EBITDA margin to 19% (our est. Sequentially, EBITDA margin has expanded ~610bp due to improved operating leverage. R&D; spend was INR1.1b, 5.5% of sales v/s 5.9% of sales in 1QFY19. PAT declined by ~21% YoY to INR2.

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

14 Sep 2018

5433.00

-1.36%

Alkem to take maximum hit from combination drug ban: Nomura

Business Line

Alkem Laboratories will take a maximum hit from the government's decision to ban 328 combination drugs, says Nomura.The Ministry of Health and Famil

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6400.0 on 19 Sep, 2025.

Alkem Laboratories Ltd.

14 Aug 2018

5433.00

-1.36%

Alkem Labs - 1QFY19 Result Update

Buy: Alkem Laboratories Ltd.

Target

Reliance Securities

ff US FDA: Alkem is yet to receive The US FDA clearance for St. Louis facility. However, it has already received EIR for Daman unit (inspected in Mar'18), while the US FDA inspected its Baddi plant between 6-10th Aug-18 with zero observations....

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6400.0 on 19 Sep, 2025.

Alkem Laboratories Ltd.

11 Aug 2018

5433.00

-1.36%

Alkem Labs (1QFY19): Growth stock. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS) Alkems 1QFY19 results were largely below our estimates. Revenue at Rs 16.7bn, was up 28.9%YoY and 10.3%QoQ. EBITDA of Rs 2.1bn grew 127%YoY with margin coming up to 12.8%, up 550bps YoY. PAT at Rs 1.4bn was 115% higher than that in 1QFY18. The impressive growth is attributed to a low GST-hit base. EBITDA, margin, and PAT missed our estimates by 21%, 380bps, and 22% YoY respectively. Domestic growth was 25.7%.

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6400.0 on 19 Sep, 2025.

Alkem Laboratories Ltd.

24 Jul 2018

5433.00

-1.36%

Alkem Labs gets EIR report from US FDA

Business Line

Alkem Laboratories has received an Establishment Inspection Report from the US Food and Drug Administration for its manufacturing facility at Amaliya

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem's Daman plant clears FDA hurdle, gets establishment inspection report

Business Standard | 24 Jul 2018

Alkem Laboratories Ltd.

31 May 2018

5433.00

-1.36%

Alkem Labs (4QFY18): Weak quarter. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 2,445 (24x FY20E EPS). The fourth quarter is seasonally weak for ALKEM, and 4QFY18 was no different. The top-line grew 21% YoY but declined 13%QoQ to Rs 15.1bn. EBITDA margin at 7.5% and PAT at Rs 745mn missed our estimates by ~440bps and 46% respectively. R&D; spend during the quarter was significant (7.4% of sales vs 6.7% expected), with 11 ANDAs filed in 4QFY18. There was also MTM loss of Rs 283mn included in other expenses for real estate investments. Adjusted for this, EBITDA margin was at 9.4% in 4QFY18.

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6400.0 on 19 Sep, 2025.

Alkem Laboratories Ltd.

04 Apr 2018

5433.00

-1.36%

Near-term overhang for Alkem Laboratories' fast growing US business

Business Standard

Any adverse outcome of the FDA's observations will impact the company's overall growth

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

28 Mar 2018

5433.00

-1.36%

Alkem Labs gets 14 USFDA observations

Business Line

Alkem Laboratories has said the US Food and Drug Administration (USFDA) has pointed out 14 observations for objectionable conditions at its manufacturing units at Amaliya in Daman and St Louis in

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Labs gets 14 USFDA observations for two units, shares fall 11%

livemint | 28 Mar 2018

Alkem Laboratories Ltd.

26 Feb 2018, 01:17PM

5433.00

-1.36%

Is Tiger Balm set for a big leap in India with Alkem as its rider?

Business Standard

Legacy brand, Tiger Balm, is overhauling its image and positioning in a new alliance with the pharmaceutical major

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

15 Feb 2018

5433.00

-1.36%

Result Update:Alkem Lab

Buy: Alkem Laboratories Ltd.

Target

Axis Direct

Strong gross margin of 64% (up 50 bps YoY/200 bps QoQ) and higher India (up 22% YoY) and US sales (up 17% QoQ) led to significant operating leverage, as EBITDA grew 34% YoY to Rs 3.6 bn (21% higher than our estimate).

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Is Alkem Laboratories Ltd. worth buying?

139 Votes:

Buy 79.14%

Sell 14.39%

Hold 6.47%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf